Cao Qi-wei, Li Hong-yan, Yao Xiao-xiang, Wang Jin-fen
Department of Pathology, Shanxi Cancer Hospital, Shanxi Medical University, Taiyuan 030013, China.
Zhonghua Xue Ye Xue Za Zhi. 2012 Dec;33(12):1010-4.
To study the expression of miR-146b-5p in diffuse large B cell lymphoma (DLBCL), and its relationship with risk assessment.
62 cases of nodal DLBCL with follow-up data were collected from Shanxi Cancer Hospital, and were studied by using immunohistochemical EnVision method for CD3, CD10, CD20, Bcl-6 and MUM1. The DLBCLs were classified into germinal center B cell-like (GCB) and non-germinal center B cell-like (non-GCB) subtypes according to Hans'algorithm. Agilent Human miRNA Microarray 16.0 was used to select the miRNAs on paraffin-embedded tissues of 24 DLBCL cases. A TaqMan real-time polymerase chain reaction (RT-PCR) method was performed on 62 nodal DLBCL cases to validate the expression levels of miR-146b-5p.11 cases with reactive lymph node were elected as control.
In 62 cases of DLBCL, 35.5% of cases were GCB and 64.5% non-GCB subtypes, the expression of miR-146b-5p in GCB was 3.2 times as much as non-GCB subtypes (P = 0.006). The expression of miR-146b-5p was up-regulated in DLBCL, and expression level of miR-146b-5p was 5.4 times as much as reactivated lymph node. In 62 cases of DLBCL, 43.5% cases were recurrence-free and 56.5% recurrence. The expression of miR-146b-5p was remarkably up-regulated in recurrence-free group compared with recurrence group (P = 0.004). Moreover, high expression levels of miR-146b-5p in DLBCL were found to be associated with longer relapse-free survival (P = 0.005), but not for overall survival. Multivariate COX proportional hazard regression analysis revealed that low expression of miR-146b-5p (P = 0.004) and IPI ≥ 3(P = 0.011) were independent poor prognostic factors in 62 cases of DLBCL.
The expression of miR-146b-5p was up-regulated in recurrence-free group, and its higher expression levels in DLBCL were associated with improved relapse-free survival. Our results suggested that miR-146b-5p might be one of markers for risk assessment.
研究miR-146b-5p在弥漫性大B细胞淋巴瘤（DLBCL）中的表达及其与风险评估的关系。
收集山西省肿瘤医院62例有随访数据的淋巴结DLBCL病例，采用免疫组织化学EnVision法检测CD3、CD10、CD20、Bcl-6和MUM1。根据Hans算法将DLBCL分为生发中心B细胞样（GCB）和非生发中心B细胞样（非GCB）亚型。使用安捷伦人类miRNA微阵列16.0对24例DLBCL石蜡包埋组织中的miRNA进行筛选。对62例淋巴结DLBCL病例采用TaqMan实时聚合酶链反应（RT-PCR）方法验证miR-146b-5p的表达水平。选取11例反应性淋巴结作为对照。
62例DLBCL中，GCB亚型占35.5%，非GCB亚型占64.5%，GCB中miR-146b-5p的表达是非GCB亚型的3.2倍（P = 0.006）。DLBCL中miR-146b-5p表达上调，其表达水平是反应性淋巴结的5.4倍。62例DLBCL中，43.5%病例无复发，56.5%复发。无复发组miR-146b-5p的表达明显高于复发组（P = 0.004）。此外，发现DLBCL中miR-146b-5p高表达与较长的无复发生存期相关（P = 0.005），但与总生存期无关。多因素COX比例风险回归分析显示，miR-146b-5p低表达（P = 0.004）和国际预后指数（IPI）≥3（P = 0.011）是62例DLBCL独立的不良预后因素。
无复发组miR-146b-5p表达上调，DLBCL中其较高表达水平与改善的无复发生存期相关。我们的结果提示miR-146b-5p可能是风险评估的标志物之一。
Zotero 插件